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Abstract
Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of
a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug
resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy.
Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hep-
atitis B (CHB) infection.
Methods: Polymerase chain reaction (PCR) amplification and direct sequencing procedures were used to analyze mutations. The de-
tected drug resistance mutations were divided into the nucleos(t)ide analogs primary, partial, and compensatory resistance groups.
The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vac-
cine - escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin
(HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitu-
tions.
Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were
hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary,
partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined
in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V,
sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8%
(n = 184), respectively.
Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB
undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for
hepatitis B is of paramount importance to monitor and control the emerging resistance.
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1. Background
Hepatitis B virus (HBV) is a prototype member of the
family Hepadnaviridae. It consists of a partially double
- stranded circular DNA genome of approximately 3200
bases with 4 overlapping open reading frames (ORFs) (1).
The 4 ORFs are the core/precore, polymerase (pol), enve-
lope (env), and X. The circular nature of the DNA and the
arrangement of the ORFs cause the env gene to completely
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overlap with the pol gene, and consequently result in im-
portant changes in hepatitis B surface antigen (HBsAg) and
a considerable reduction in HBsAg - specific antibodies
(anti - HBs) binding in vitro (2).
The high magnitude of HBV replication leads to the
considerable production of virions (> 1012) during each
replicative cycle of the virus. As the reverse transcriptase
(rt) encoded by the pol gene lacks a proofreading activity,
HBV replication is associated with a high mutation rate of
10 -5 substitutions/base/cycle. This results in the generation
of all possible single - base changes in the genome, includ-
ing single and double mutations, which in turn are respon-
sible to develop nucleos(t)ide analogs (NUCs) resistance in
patients before and during NUCs therapy (3).
The NUCs treatment strategies should be implemented
as early as possible following the detection of drug - re-
sistant HBV variants, especially before the virological and
clinical breakthrough (4). Mutations may occur primary
and secondary forms. Primary drug resistance mutations
tend to reduce the susceptibility to an antiviral agent.
However, secondary compensatory mutations repair repli-
cation defects related to primary drug resistance (5).
Turkey is one of the countries with a prevalence of 2%
to 8% of intermediate endemicity for HBV infecion (6, 7).
In a systematic review in Turkey, the estimated overall pop-
ulation with HBV prevalence was 4.57%, whereas the esti-
mated total number of patients with chronic hepatitis B
(CHB) was 3.3 million. However, the prevalence varied in
different regions of the country; the prevalence was 3.47%
and 6.72% in the Western and Eastern regions, respectively
(8, 9).
With this background, the current study aimed at in-
vestigating the molecular characterization of HBV in Turk-
ish patients with CHB.
2. Methods
2.1. Patients
The current study was conducted from 2010 to 2015 on
762 patients chronically infected with HBV from 7 regions
and 35 clinics in 25 cities across Turkey. Due to the un-
successful DNA sequencing reactions, 110 and 124 patients
in the treatment - naive and treatment - experienced cat-
egories were excluded from the study, respectively. The
clinical and demographic characteristics of the patients
are mentioned in Table 1. The study consisted of 528 pa-
tients, treatment - naive (n = 271, 51.3%) and those under
NUCs treatment (n = 257, 48.7%). All the patients were clas-
sified as HBV chronic carriers according to the European
Association for the Study of the Liver (EASL) clinical prac-
tice guidelines (10). The study was also approved by the
clinical research ethics committee of Kocaeli University
(Project no. KKAEK 2009/24; date: November 24, 2009; ap-
proval no. 5/16), and written informed consent was ob-
tained from each patient before entering the study. Blood
samples were obtained before starting the therapy and
during the viral breakthrough of the treatment. The sam-
ples were centrifuged immediately, and the sera were sep-
arated, aliquoted, and then, stored at - 20°C until use. Sero-
logical markers of HBV were measured by enzyme - linked
immunosorbent assay (ELISA) in all local clinic units.
2.2. HBV DNA Detection
HBV DNA was isolated from the serum samples ob-
tained from the patients on the BioRobot workstation us-
ing the magnetic particle technology (QIAsymphony SP;
Qiagen GmbH, Hilden, Germany). HBV DNA was detected
by a commercial real - time polymerase chain reaction
(PCR) assay (Artus HBV QS - RGQ test; Qiagen GmbH, Hilden,
Germany) on the real - time platform (Rotor - Gene Q; Qia-
gen GmbH, Hilden, Germany).
2.3. HBV pol Gene Sequencing
Specific primer pairs were constructed (forward:
5’ - TCGTGGTGGACTTCTCTCAATT - 3’ and reverse: 5, -
CGTTGACAGACTTTCCAATCAAT - 3’) for the amplification
of the HBV pol gene region (11). The PCR conditions were
as follows: denaturation at 95°C for 10 minutes followed
by 35 cycles consisting of an annealing step at 95°C for
45 seconds, extension at 60°C for 45 seconds, and a final
step at 72°C for 45 seconds. The final concentration of the
primers was 0.3 mM. The size of the derived amplicon in
HBV was approximately 742 bp and included all the known
NUCs resistance mutations in HBV. Phire Hot Start DNA
polymerase (Finnzymes Oy, Vantaa, Finland) was utilized
in the sequencing protocol. All PCR products were purified
using the High Pure PCR product purification kit (Roche
Diagnostics, Mannheim, Germany). Sequencing was per-
formed using an ABI PRISM 3130 genetic analyzer (applied
biosystems Inc., Foster City, California, United States). The
BigDye Terminator version 3.1 Cycle Sequencing Kit (Amer-
sham Pharmacia Biotech Inc., Piscataway, New Jersey,
United States), 36 cm capillary array, and POP - 7TM polymer
(applied biosystems Inc.) were used for sequencing. For
cycle sequencing, the following thermal protocol was
used: 35 cycles consisting of 95°C for 20 seconds, 50°C for
25 seconds, and finally 60°C for 2 minutes. The reverse and
sequencing primers were used at a final concentration of
0.5 mM.
2 Hepat Mon. 2018; 18(1):e12472.
Asan A et al.
2.4. HBV pol/surface Gene Mutation Determination
The sequencing data were analyzed using the
Genafor/Arevir - geno2pheno drug resistance tool (cen-
ter of advanced European studies and research; Bonn,
Germany [http://coreceptor. bioinf.mpi - inf.mpg.de]).
The geno2pheno tool for HBV is a database specifically
designed for the rapid computer - assisted virtual pheno-
typing of Hepatitis B and utilizes genome (nucleic acid)
sequences as input. The program searches for homology
between the input sequence and other DNA sequences
already stored in its database, including relevant clinical
data for drug resistance and surface gene mutations (12).
The tool searches for HBV drug resistance mutations in
the rt domain of the polymerase at amino acid positions
80 to 250 (13). Drug resistance mutations to the NUCs
were categorized into primary, partial, and compensatory
resistance groups (14).
The overlapping S - gene segment was obtained using
the geno2pheno tool for amino acid substitutions at po-
sitions from 100 to 196 (15). The amino acid substitutions
in HBsAg were categorized into antiviral drug - associated
potential vaccine - escape mutants (ADAPVEMs) and typical
HBsAg amino acid substitutions. The latter included hep-
atitis B hyperimmunoglobulin (HBIg) - selected escape mu-
tation, vaccine escape mutation, hepatitis B misdiagnosis,
and immune - selected amino acid substitutions (5, 14, 16-
19).
Some mutations, especially ADAPVEMs, were not lo-
cated in the “a” determinant of the HBsAg protein. Further,
the important neutralizing domains of the HBsAg protein
including the region outside the “a” determinant of the
HBsAg protein for ADAPVEMs were analyzed.
2.5. Statistical Analysis
Statistical analysis was performed using IBM SPSS
Statistics software, version 21.0 for Windows (SPSS; IBM cor-
poration, New York, United States). The chi - square and
t tests were utilized in the statistical analysis. A P value <
0.05 was considered significant.
3. Results
The current study consisted of a total of 528 patients,
of which 325 (61.6%) were male with a mean age of 38 years
(range: 18 - 69). Based on their HBeAg status, 351 (66.3%) pa-
tients were HBeAg - negative. Seven patients were anti - HIV
antibody positive, 4 were anti - HDV IgG positive, and 1 pa-
tient was anti - HCV positive (Table 1).
The number and percentage of male patients in the
treatment - naive and treatment - experienced groups were
170 (62.7%) and 155 (60.3%) (P = 0.56), respectively. The
HBeAg positivity in these groups was detected in 65 pa-
tients (24.0%) and 113 patients (44.0%) (P = 0.01), respec-
tively.
The patients in the treatment - naive and treatment
- experienced groups reported a mean ± standard devia-
tion (SD) age of 39.32± 11.47 and 38.38± 12.72 years, mean
HBV viral load of 8.5 + E7 (± 6.6 + E8) and 6.2 + E7 (± 6.5
+ E9) IU/mL, mean alanine aminotransferase (ALT) levels
of 69.99± 199.84 and 73.68± 107.92 U/L, and mean aspar-
tate transaminase (AST) levels of 51.01 ± 110.44 and 50.18
± 60.12 U/L, respectively. The differences in age, HBV viral
load, ALT, and AST levels in the patients in the treatment -
naive and treatment - experienced groups were not signifi-
cant according to t test results (P = 0.43, 0.71, 0.81, and 0.92,
respectively).
Among 50 (18.5%) and 112 (43.6%) patients in the treat-
ment - naive and treatment - experienced groups, respec-
tively, there were 191 (70.5%) and 142 (55.3%) patients in
HBeAg - negative CHB phase and immune - reactive phase,
respectively (P = 0.01).
The patients were administered lamivudine (LAM,
33.5%), combination therapy (27.6%), tenofovir (TDF, 14.0%),
entecavir (ETV, 11.7%), PEGylated interferon (5.4%), telbivu-
dine (Ldt) (3.9%), and adefovir (ADV, 3.9%) at the time of viral
rebound in the treatment - experienced group.
Genotype D was identified in 526 patients (99.6%), and
genotype H only in 2 naive patients (0.4%) (Table 1). How-
ever, subgenotypes D1, D2, D3, and D4 were determined in
461 (87.3%), 29 (5.5%), 30 (5.7%), and 6 (1.1%) patients, respec-
tively.
In total, 174 (32.9%) Turkish patients with mutations in
the HBV pol gene were primary, partial, or compensatory
resistant to NUCs. Among them, 79 (45.4%) patients be-
longed to the treatment - naive group, whereas 95 (54.6%)
belonged to the treatment - experienced group. The preva-
lence of the mutation in the gene encoding HBV poly-
merase in the treatment - experienced patients was statis-
tically different from those of the patients in the treatment
- naive group (P = 0.05). The most common primary re-
sistance mutation both in the treatment - naive and treat-
ment - experienced patients was rtM204I/V ± rtV173L ±
rtL180M. The frequencies and patterns of mutations in the
HBV pol gene are displayed in Table 2.
The total prevalence of typical amino acid substitu-
tions in HBsAg was 34.8% (n = 184). According to the treat-
ment status, the prevalence was 33.5% (n = 91) and 36.1%
(n = 93) in the treatment - naive and treatment - experi-
enced patients, respectively. The HBIg escape mutation,
vaccine escape mutation, misdiagnosis, and immune - se-
lected escape mutations were 8.3%, 4.1%, 3.8%, and 18.6%, re-
spectively. There was no statistically significant difference
in the prevalence of HBsAg escape amino acid substitu-
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Table 1. Clinical and Demographic Characteristics of the Patients
Variables Value
Patients, no 528
Gender, M/F, (%) 325/203 (61.6/38.4)
HBeAg positivity, n (%) 178 (33.7)
ALT,median (range) U/L 37 (9 - 2584)
HBVDNA load,median (range) IU/mL 1.3 E+4 (6 E+2 - 9.8 E+6)
Participation fromRegionsa , n (%)
Marmara (Balikesir, Bursa, Edirne, Istanbul, Kocaeli) 218 (41.3)
Central Anatolia (Ankara, Konya, Kayseri) 104 (19.7)
South - eastern Anatolia (Adiyaman, Batman, Diyarbakir, Antep, Urfa) 73 (13.8)
Black Sea (Bolu, Giresun, Sakarya, Samsun, Tokat) 55 (10.4)
Aegean (Afyon, Denizli, Izmir) 48 (9.1)
Mediterranean (Antalya, Maras, Mersin, Osmaniye) 30 (5.7)
Clinical status, n (%)
HBeAg negative CHB phase 333 (63.1)
Immune reactive phase 162 (30.7)
Inactive HBV carrier state phase 18 (3.4)
Immune tolerant phase 15 (2.8)
HBV genotype, n (%) D: 526 (99.6) ; H: 2 (0.4)
HBV subgenotype of genotype D, n (%) D1: 461 (87.7 ); D2: 29 (5.5); D3: 30 (5.7); D4: 6 (1.1)
Co - infection status, n (%)
Anti - HCV positive 1 (0.2)
Anti - HDV IgG positive 4 (0.8)
Anti - HIV positive 7 (1.3)
Treatment status, n (%)
Treatment - naive 271 (51.3)
Treatment - experienced 257 (48.7)
Drug choice statusb , n(%)
Lamivudine 86 (33.5)
Combination 71 (27.6)
Tenofovir 36 (14.0)
Entecavir 30 (11.7)
Interferon 14 (5.4)
Telbivudin 10 (3.9)
Adefovir 10 (3.9)
Abrrevations: CHB, chronic hepatitis B; F, female; M, male.
aPatients included 35 different clinics from 25 cities in Turkey.
bTherapy situation during rebound.
tions in the treatment - naive and treatment - experienced
patients (P = 0.57). Typical patterns of amino acid substi-
tutions in the HBsAg escape mutants are depicted in Table
3.
Six different ADAPVEM motifs were located both in the
treatment - naive and treatment - experienced patients.
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Table 2. Characteristics of Genotypic Resistance Mutations to the Nucleos(t)ide Analogues
Mutation Characteristic, No.
(%)
Mutation Pattern Nucleos(t)ide Analogue Patient No. (%) P Value
Naive Experienced
Primary ResistanceMutation
n = 84 (15.9)
rtA181G/S/T/V LAM, LdT, L - FMAU, ADV, TDFa 1 (0.18) 8 (1.5)
0.01
rtT184A/I/L ETVa 0 9 (1.7)
rtM204I/V± rtV173L± rtL180M LAM, LdT, L - FMAU, FTC 9 (1.8) 50 (9.4)
rtM204V + rtT184S LAM, LdT, ETV 0 1 (0.18)
rtI233V ADV 3 (0.5) 1 (0.18)
rtN236T ADV, TDF 1 (0.18) 1 (0.18)
Total 14 (2.6) 70 (13.2)
Partial ResistanceMutation
n = 20 (3.7)
rtT184L ETV 0 1 (0.18)
0.06
rtA194S/T/X TDF 4 (0.7) 6 (1.1)
rtS202G ETV 1 (0.18) 6 (1.1)
rtM250V/R ETV 1 (0.18) 1 (0.18)
Total 6 (1.1) 14 (2.6)
CompensatoryMutation n =
143 (27.0)
rtL91I LdT 23 (4.3) 23 (4.3)
0.09
rtQ149K ADV 19 (3.5) 15 (2.8)
rtV191I TDF 0 1 (0.18)
rtV214A LAM, L - FMAU, FTC, TDF 2 (0.3) 3 (0.5)
rtQ215H/P/S LAM, L - FMAU, FTC, TDF 37 (7) 18 (3.4)
rtN238D ADV 1 (0.18) 1 (0.18)
Total 82 (15.5) 61 (11.5)
aPropable resistance
They were sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T,
sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The to-
tal prevalence of ADAPVEMs was 2.9% (n = 8) and 7.7% (n =
20) in the treatment - naive and treatment - experienced
groups, respectively. The prevalence of ADAPVEMs in the
treatment - experienced patients was statistically differ-
ent from that of the treatment - naive patients (P = 0.03).
The ADAPVEM patterns were related to LAM, LdT, and ADV
drugs. The ADAPVEMs motifs in the treatment - naive and
treatment - experienced patients are displayed in Table 4.
4. Discussion
The current study focused on analyzing the prevalence
of mutations in the Turkish people chronically infected
with HBV. Six different primary resistance mutation pat-
terns were detected in 84 (48.2%) patients. Fourteen (8%) of
them belonged to the treatment - naive, whereas 70 (40.2%)
of them belonged to the treatment - experienced group.
However, the most common primary resistance mutation
was reported rtM204I/V ± rtV173L ± rtL180M. The preva-
lence of primary resistance mutations in the treatment -
experienced patients was statistically different from that
of the treatment - naive patients (P = 0.01), indicating that
primary resistance mutations occurred mainly in patients
with the use of NUCs during treatment. The viral rebounds
during antiviral treatment should be analyzed in terms
of drug resistance. Antiviral resistance can be detected
prior to treatment; therefore, screening to detect resis-
tance prior to the commencement of treatment may be re-
garded as a rational approach. The primary resistance mu-
tations associated with amino acid positions 181, 204, 233,
and 236 were detected in the treatment - naive patients.
Sayan et al., reported 2 resistance mutations (rtI233V and
rtN236T) associated with acyclic phosphonates (ADV); how-
ever, the group could not detect YIMM or YMDD mutations
in patients with naive - CHB in Turkey (11). The current study
findings suggested a possible accumulation of primary re-
sistance mutations for NUCs, which may be attributed to
their widespread use in the last 5 years in Turkey.
The available literature reports an overall prevalence of
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Table 3. Typical HBsAG Escape Amino Acid Substitutions of the Study Patients
HBsAg Amino Acid
Substitution
Category
Mutation Pattern Patient No. (%) Combined Pattern Number of
Patients
P Value
Naive Experienced
HBIg escape sT118A, sP120T,
sT123A,sQ129R,
sM133L,
sY134N,sD144E,
sG145K
23 (8.4) 21 (8.2) sT123A + sG145K 2a 0.89
Vaccine escape sP120S, sM133L,
sS143L,sD144E,
sG145R, sS193L
10 (3.7) 12 (4.6) 0.57
Hepatitis B
misdiagnosis
sP120S/T, sR122K,
sT131I, sM133T, sS143L
11 (4) 9 (3.5) 0.73
Immune - selected
amino acid
substitution
sQ101H/R, sI110L,
sG119I/R,
sP120T,T123A/N,
sP127T, sG130K/R,
sT131N, sT140I,
sS143T, sD144E,
sG145R
47 (17.3) 51 (19.8)
sS143T + sD144E +
sG145R
1a
0.46
sI110L + sP120T 2a
sQ101H + sI110L 1a
sQ101H + sP127T 1a
sQ101H + sI110L +
P120T
1a
Total 91(33.5) 93 (36.1)
aNumber of combined pattern patients included to the mutation pattern.
Table 4. ADAPVEM according to nucleos(t)ide analogues in treatment naive and experienced patients
Mutation
Characteristic
Mutation Pattern Nucleos(t)ide
Analogue
Patient, N (%) P Value
Treatment - Naive Treatment -
Experienced
ADAPVEMN = 28a (5.3)
sF161L/rtI169X ETV 1 -
0.03
sE164D/rtV173L +
sS195M/rtM204V
LAM, LdT - 3
rtA181T/sL172L ADV - 1
rtA181V/sL173F ADV - 3
sS195M/rtM204V LAM, LdT 4 7
sS196L/rtM204I LAM, LdT 3 6
Total 8 (2.9) 20 (7.7)
Abbreviation: ADAPVEM, antiviral drug - associated potential vaccine - escape mutant; ADV, adefovir; LAM, lamivudine; LdT, telbivudine.
aSome of the patients had multiple mutations, however the percentage of mutation was calculated for 28 patients.
primary resistance mutations among treatment - naive pa-
tients to range from 1% to 30%. Such variability is likely to
occur due to the differences in the methods applied to de-
termine the mutation in the HBV pol gene, overall study
design, and study population (20-29). However, Sayan et
al., mentioned that the direct sequencing approach could
limit the detection of primary resistance mutations (11). In
the current study, the major primary resistance mutation,
namely rtM204I/V, was usually found in combination with
other mutation patterns both in the treatment - naive and
treatment - experienced patients (30). The combination
status regarding the rtM204V mutation may serve as a use-
ful tool when selecting the study methodology.
The current study detected and characterized 4 differ-
ent partial resistance mutations. They were mainly asso-
ciated with ETV (rtT184L, rtS202G, and rtM250R/V). How-
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ever, in half of the patients, the mutations in ADV gene
(rtA194S/T/X) were detected. Patients carrying these muta-
tions and undergoing a long - term therapy may require
frequent monitoring for primary drug resistance against
ETV and TDF (31, 32). The national insurance policy cov-
ered only LAM, Ldt, and interferons for first - line treatment
(patients with HBV DNA < 2 E + 6 IU/mL). Until July 2015,
the choice of treatment for CHB was limited; therefore, the
current study did not discuss the type and duration of the
therapy.
The most common compensatory mutations in the
current study were rtQ215H/P/S, rtL91I, and rtQ149K in ei-
ther single or combined profiles both in treatment - naive
and treatment - experienced patients. The rtQ215H sub-
stitution was detected in patients receiving LAM or ADV
therapy; however, its virological and clinical importance
remained unclear (33). The primary function of compen-
satory mutations is to repair replication defects in viral
polymerase activity related to the generation of primary
drug resistance (11, 30, 34). Therefore, compensatory mu-
tations can be detected during viral rebound, but without
primary resistance during the NUCs therapy in patients
with chronic hepatitis B. These, in turn, may assist to dis-
criminate from primary drug resistance. Compensatory
mutations without any primary or partial resistance muta-
tions were detected in 27 patients in the treatment - naive
and in 59 patients in the treatment - experienced groups.
The substitution mutation, rtQ215, occurred even without
exogenous selection pressures (35).
In the current study, six different types of ADAPVEMs
were determined in Turkish patients with CHB predomi-
nantly associated with L - nucleosides (LAM and LdT) and
ADV. However, ADAPVEMs were mainly observed in pa-
tients undergoing NUCs therapy (Table 4). The data gath-
ered in the current study coincided with the findings of
other studies (11, 36, 37), particularly, the frequency of
rtM204I/V + sI195 M/sW196S/L mutations in LAM - resistant
cases demonstrated a predominant presence (34). Thus,
the ADAPVEMs can adversely affect the local or global im-
munization programs to control HBV with a potential to
spread to individuals vaccinated against HBV infection (18,
19, 38, 39).
In the HBV genome, the HBV polymerase gene and en-
velope gene completely overlap (40); hence, the mutations
in the pol ORF can cause alterations in the overlapping HB-
sAg. Typical HBsAg escape mutations were detected in the
4 categories of the patients. The immune - selected amino
acid substitution category was the most common HBsAg
amino acid substitution. However, some categories, such
as HBIg escape and immune - selected mutations demon-
strated certain patterns. Some typical HBsAg escape mu-
tations, commonly detected in the patients with CHB, are
sP120T, sM133I, sS143L, SD144A/E, sG145R, and sE164D (13, 14,
41). Typical HBsAg escape mutations may result as a con-
sequence of a failure to control infection with vaccination
or HBIg and misdiagnosis in the HBsAg testing stage (2).
Patients with CHB undergoing NUCs treatments should be
surveyed for typical HBsAg escape mutations for the bene-
fit of public health (30, 41).
The determination of viral genotypes assists to analyze
the progression of the disease, thereby aid to develop a
suitable anti - viral therapy. Genotype D is widespread in
Turkey and other Mediterranean countries (41, 42). D1 was
more frequent with the presence of D1 - D4 subgenotypes in
Turkey (43). The determination of genotypes and subgeno-
types of HBV may contribute to accurate data generation
associated with their circulation and transmissibility.
The coinfection data were very limited in Turkey; the
coinfection of HBV/HIV, HBV/HDV, and HBV/HDV was 1.3%,
0.8%, and 0.2%, respectively. In a single large - scale study,
Sayan et al., analyzed 1306 HIV - positive patients and coin-
fection of HIV/HBV was 2.7%. Sexual contact was reported
as the acquisition route in 98.6% of the patients, whereas
the use of injection drug was only 0.3% (44). Amiri et al.,
reported the coinfection of HBV/HIV as 1.8% and concluded
that the use of injection drug severely affected the degree
of coinfection (45). Both of the references 44 and 45 are re-
gional (from Turkey and Iran).
In conclusion, the findings on drug resistance muta-
tions in the treatment group require rational approaches
such as prevention of unnecessary drug modifications due
to compensatory mutations. The increasing incidence of
drug resistance mutations warrants an analysis of drug re-
sistance as an integral part to manage patients with CHB
using NUCs. In addition, the surveillance of drug resis-
tance mutations when treating HBV should be regarded
as an area of supreme importance both for regional and
global control of CHB.
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